Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
View my most recent publications at PubMed
Since the advent of targeted cancer therapies in the mid-2000s, there has been a dramatic reduction in cytoreductive nephrectomies. Dr. Michael Blute of Massachusetts General Hospital states that the reduction is concerning, since cytoreductive nephrectomy can provide a strong survival advantage to patients with metastatic disease.
The MGH Department of Urology is working to increase awareness of the second leading cause of cancer death in men and other prostate related health concerns. Michael Blute answers questions about what men can do to protect themselves and their loved ones.
Back to Top